374 related articles for article (PubMed ID: 9357533)
21. QSAR study of natural estrogen-like isoflavonoids and diphenolics from Thai medicinal plants.
De-Eknamkul W; Umehara K; Monthakantirat O; Toth R; Frecer V; Knapic L; Braiuca P; Noguchi H; Miertus S
J Mol Graph Model; 2011 Apr; 29(6):784-94. PubMed ID: 21334935
[TBL] [Abstract][Full Text] [Related]
22. Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7).
McManaway ME; Jagoda EM; Eckelman WC; Larson SM; Francis BE; Gibson RE; Reba RC; Lippman ME
Cancer Res; 1986 May; 46(5):2386-9. PubMed ID: 3697981
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides.
Taylor AH; al-Azzawi F; Pringle JH; Bell SC
Anticancer Res; 2002; 22(6C):3993-4003. PubMed ID: 12553024
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
25. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro.
Lam HY; Ng PK; Goldenberg GJ; Wong CM
Cancer Treat Rep; 1987 Oct; 71(10):901-6. PubMed ID: 3652053
[TBL] [Abstract][Full Text] [Related]
27. 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
Zheng J; Kulp SK; Zhang Y; Sugimoto Y; Dayton MA; Govindan MV; Brueggemeier RW; Lin YC
Anticancer Res; 2000; 20(1A):11-9. PubMed ID: 10769629
[TBL] [Abstract][Full Text] [Related]
28. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness.
Klotz DM; Castles CG; Fuqua SA; Spriggs LL; Hill SM
Biochem Biophys Res Commun; 1995 May; 210(2):609-15. PubMed ID: 7755640
[TBL] [Abstract][Full Text] [Related]
30. New aspects in the development of cytotoxic-linked estrogens for the control of breast neoplasia.
Leclercq G
Arch Geschwulstforsch; 1981; 51(7):643-9. PubMed ID: 7337547
[TBL] [Abstract][Full Text] [Related]
31. A novel study on the effect of acetylsalicylic acid on the binding capacity of estrogen receptors from MCF-7 cells.
van Aswegen C; Dirksen van Schalkwyk JC; Roux LJ; Becker PJ; Du Plessis DJ
Clin Physiol Biochem; 1992; 9(4):145-9. PubMed ID: 1302170
[TBL] [Abstract][Full Text] [Related]
32. Specific estrogen receptor binding and biological effects of 16 alpha-iodoestradiol on human breast cancer cells.
Lippman ME; Do HM; Hochberg RB
Cancer Res; 1981 Aug; 41(8):3150-4. PubMed ID: 7248972
[TBL] [Abstract][Full Text] [Related]
33. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells.
Erber S; Ringshandl R; von Angerer E
Anticancer Drug Des; 1991 Nov; 6(5):417-26. PubMed ID: 1764164
[TBL] [Abstract][Full Text] [Related]
34. Quantitative structure-activity relationship studies of threo-methylphenidate analogs.
Misra M; Shi Q; Ye X; Gruszecka-Kowalik E; Bu W; Liu Z; Schweri MM; Deutsch HM; Venanzi CA
Bioorg Med Chem; 2010 Oct; 18(20):7221-38. PubMed ID: 20846865
[TBL] [Abstract][Full Text] [Related]
35. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to the estrogen receptor of MCF-7 cells in cytosolic extracts and in nuclei of intact cells.
Schütze N; Vollmer G; Wünsche W; Grote A; Feit B; Knuppen R
Exp Clin Endocrinol; 1994; 102(5):399-408. PubMed ID: 7867704
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of an average mammalian estrogen receptor-based QSAR model.
Mekenya O; Kamenska V; Serafimova R; Poellinger L; Brouwer A; Walker J
SAR QSAR Environ Res; 2002 Oct; 13(6):579-95. PubMed ID: 12479373
[TBL] [Abstract][Full Text] [Related]
37. Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity.
Duax WL; Swenson DC; Strong PD; Korach KS; McLachlan J; Metzler M
Mol Pharmacol; 1984 Nov; 26(3):520-5. PubMed ID: 6548545
[TBL] [Abstract][Full Text] [Related]
38. Estrogen conjugates and serum factors mediating the estrogenic trophic effect on MCF-7 cell growth.
Devleeschouwer N; Legros N; Olea-Serrano N; Paridaens R; Leclercq G
Cancer Res; 1987 Nov; 47(22):5883-7. PubMed ID: 3664489
[TBL] [Abstract][Full Text] [Related]
39. Estrogenic triarylethylene acetic acids: effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells.
Ruenitz PC; Bourne CS; Sullivan KJ; Moore SA
J Med Chem; 1996 Nov; 39(24):4853-9. PubMed ID: 8941399
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
